|MDACC Study No:||2006-0472 (clinicaltrials.gov NCT No: NCT00671801)|
|Title:||Phase I/II Trial of Irinotecan plus Lenalidomide in Adult Patients with Recurrent Glioblastoma Multiforme|
|Principal Investigator:||John DeGroot|
|Treatment Agent:||Irinotecan; Lenalidomide|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of lenalidomide combined with Camptosar (irinotecan) as well as to see if this
drug combination can help control malignant gliomas.
Researchers will also study if a special magnetic resonance imaging (MRI)
technique (dynamic MRI scan) is useful in looking at the effect of treatment on
the tumor. Another goal is to learn the effect of lenalidomide on tumor tissue
in patients who need surgery for the disease.